Loading...
Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia Resistant to Imatinib at a Dose of 400 to 600 Milligrams Daily: Two-Year Follow-Up of a Randomized Phase 2 Study (START-R)
BACKGROUND: In patients with chronic-phase chronic myeloid leukemia (CP-CML), imatinib resistance is of increasing importance. Imatinib dose escalation was the main treatment option before dasatinib, which has 325-fold more potent inhibition than imatinib against unmutated Bcr-Abl in vitro. Data wit...
Na minha lista:
| Udgivet i: | Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2009
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5345391/ https://ncbi.nlm.nih.gov/pubmed/19536906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24504 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|